1,704 reports of this reaction
4.6% of all RIFAXIMIN reports
#2 most reported adverse reaction
HOSPITALISATION is the #2 most commonly reported adverse reaction for RIFAXIMIN, manufactured by Salix Pharmaceuticals, Inc.. There are 1,704 FDA adverse event reports linking RIFAXIMIN to HOSPITALISATION. This represents approximately 4.6% of all 37,072 adverse event reports for this drug.
Patients taking RIFAXIMIN who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is moderately reported among RIFAXIMIN users, representing a notable but not dominant share of adverse events.
In addition to hospitalisation, the following adverse reactions have been reported for RIFAXIMIN:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 1,704 FDA reports for RIFAXIMIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 4.6% of all adverse event reports for RIFAXIMIN, making it one of the most commonly reported side effect.
If you experience hospitalisation while taking RIFAXIMIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.